Diagnosis of mast cell activation syndrome: a global “consensus-2”

B. Afrin, Lawrence; B. Ackerley, Mary; S. Bluestein, Linda; Brewer, Joseph; Brook, Jill; D. Buchanan, Ariana; R. Cuni, Jill; P. Davey, William; T. Dempsey, Tania; R. Dorff, Shanda; S. Dubravec, Martin; G. Guggenheim, Alena; J. Hindman, Kimberly; Hoffman, Bruce; L. Kaufman, David; J. Kratzer, Stephanie; M. Lee, Theodore; S. Marantz, Mindy; J. Maxwell, Andrew; K. McCann, Kelly; L. McKee, Dwight; Menk Otto, Laurie; Pace, Laura; D. Perkins, Dahra; Radovsky, Laurie; S. Raleigh, Mary; A. Rapaport, Sonia; Reinhold, Emma; L. Renneker, Mark; A. Robinson, William; M. Roland, Aaron; Scott Rosenbloom, E.; C. Rowe, Peter; S. Ruhoy, Ilene; Saperstein, David; A. Schlosser, David; R. Schofield, Jill; E. Settle, Janet; B. Weinstock, Leonard; Wengenroth, Martina; Westaway, Mark; Cindy Xi, Shijun; J. Molderings, Gerhard

doi:10.1515/dx-2020-0005

Public

Diagnosis of mast cell activation syndrome: a global “consensus-2”

Published in Diagnosis • Apr 22, 2020

Authors:

Lawrence B. Afrin

Mary B. Ackerley

Linda S. Bluestein

Abstract

The concept that disease rooted principally in chronic aberrant constitutive and reactive activation of mast cells (MCs), without the gross MC neoplasia in mastocytosis, first emerged in the 1980s, but only in the last decade has recognition of "mast cell activation syndrome" (MCAS) grown significan...

Subject

Overdiagnosis

Consensus conference

Population

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!